FindTrial
Sign In

EFFECT OF DRUG NISHAMLAKI IN PCOS

Effect of Nishamlaki in patients of Polycystic Ovarian Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/009111
Enrollment
24
Registered
2017-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- polycystic ovarian syndrome Health Condition 2: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Nishamlaki: 4mg oral OD for 3 months Control Intervention1: Metformin: As per clinicians advice oral OD for 3 months

Sponsors

Pharmaza Herbals Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: females diagnosed with polycystic ovarian syndrome

Exclusion criteria

Exclusion criteria: patients with 1.known liver,kidney,heart disease 2.complaining of infertility 3.active infection such as HIV, tuberculosis,hepatitis,etc 4.assosiated cervical and/or uterine pathologies like fibroid,polyp, endometriosis,etc 5.congenital anamolies related to genital tract 6.other endocrinal abnormalities

Design outcomes

Primary

MeasureTime frame
1.reduction in insulin Resistance 2.regularization of menstrual cycles Timepoint: at the end of 3 months—

Secondary

MeasureTime frame
1. Reduced number of ovarian cysts 2. Reduction in signs of hyperandrogenismTimepoint: at the end of 3 months—

Countries

India

Contacts

Public ContactDr Kalyani N Khade

Bharati Vidyapeeth Pune

drvpandit@yahoo.co.in9371003390

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026